Search

Displaying results 1221 - 1230 of 5300 in total
  1. Drug

    Remtolumab

    go.drugbank.com/drugs/DB15128
    Investigational

    Remtolumab is under investigation in clinical trial NCT02433340 (Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12

  2. Drug

    MVR-C5252

    go.drugbank.com/drugs/DB30379
    Investigational

    MVR-C5252 is under investigation in clinical trial NCT06126744 (Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252).

  3. Drug

    Technetium Tc-99m nofetumomab merpentan

    go.drugbank.com/drugs/DB09336
    ApprovedWithdrawn

    It was after discontinued on August 13, 2013, but in the 2018 FDA submission list, it can be found as a substance type II (Drug substance) with an active status.[L1650, L1082] … Technetium Tc-99m nofetumomab merpentan (Tc-99m nm) consists of a Fab fragment of an IgG2b of the pancarcinoma murine antibody NR-LU-10.

  4. Drug

    Coagulation factor VII human

    go.drugbank.com/drugs/DB13150
    ApprovedInvestigational

    Coagulation factor VII is human serine protease type enzyme that is involved in the extrinsic coagulation cascade which results in blood clotting.

    Categories: coagulation factor IX, II, VII and X in combination
  5. Drug

    Trifluridine

    go.drugbank.com/drugs/DB00432
    ApprovedInvestigational

    cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. … It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus.

  6. Drug

    Patisiran

    go.drugbank.com/drugs/DB14582
    Approved

    Patisiran is a first in class short interfering RNA for the treatment of patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis . It is marketed as Onpattro which is formulated as patisiran within a liposome...

  7. Drug

    Danaparoid

    go.drugbank.com/drugs/DB06754
    ApprovedWithdrawn

    Danaparoid possesses a potent antithrombic activity that works by inhibiting activated factor X (Factor Xa) and activated factor II (Factor IIa). … Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans [A32565].

  8. Drug

    Palbociclib

    go.drugbank.com/drugs/DB09073
    ApprovedInvestigational

    Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmac...

  9. Drug

    Oxycodegol

    go.drugbank.com/drugs/DB14146
    Investigational

    Loxicodegol was developed by Nektar Therapeutics as an opioid analgesic with low abuse potential for the treatment of chronic pain [L3263]. … Nektar Therapeutics has filed an application for FDA approval of Loxicodegol for use in the treatment of chronic lower back pain [L3263]

  10. Drug

    Iodine povacrylex

    go.drugbank.com/drugs/DB09537
    Approved

    It is a broad spectrum antiseptic and can provide almost 99.9% antiseptic conditions. It is intended for local use only. … DuraPrep solution is indicated for use as a patient preoperative skin preparation, for the preparation of the skin prior to surgery and to help reduce bacteria that can potentially cause skin infection